Parkinson Disease — Effects of Gait Rehabilitation With Dual Task in Patients With Parkinson's Disease
Citation(s)
Brauer SG, Morris ME Can people with Parkinson's disease improve dual tasking when walking? Gait Posture. 2010 Feb;31(2):229-33. doi: 10.1016/j.gaitpost.2009.10.011. Epub 2009 Dec 6.
Canning CG, Ada L, Woodhouse E Multiple-task walking training in people with mild to moderate Parkinson's disease: a pilot study. Clin Rehabil. 2008 Mar;22(3):226-33. doi: 10.1177/0269215507082341.
Fok P, Farrell M, McMeeken J Prioritizing gait in dual-task conditions in people with Parkinson's. Hum Mov Sci. 2010 Oct;29(5):831-42. doi: 10.1016/j.humov.2010.06.005. Epub 2010 Aug 19.
Fok P, Farrell M, McMeeken J The effect of dividing attention between walking and auxiliary tasks in people with Parkinson's disease. Hum Mov Sci. 2012 Feb;31(1):236-46. doi: 10.1016/j.humov.2011.05.002. Epub 2011 Jul 1.
Yogev-Seligmann G, Giladi N, Brozgol M, Hausdorff JM A training program to improve gait while dual tasking in patients with Parkinson's disease: a pilot study. Arch Phys Med Rehabil. 2012 Jan;93(1):176-81. doi: 10.1016/j.apmr.2011.06.005. Epub 2011 Aug 1
Effects of Gait Rehabilitation With Dual Task in Patients With Parkinson's Disease: a Randomized Controlled Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
